Lilly C M, Martins M A, Drazen J M
Department of Medicine, Beth Israel Hospital, Boston, Massachusetts.
J Clin Invest. 1993 Jan;91(1):235-43. doi: 10.1172/JCI116176.
The effects of enzyme inhibitors on vasoactive intestinal peptide (VIP)-induced decreases in airway opening pressure (PaO) and VIP-like immunoreactivity (VIP-LI) recovery were studied in isolated tracheal superfused guinea pig lungs. In the absence of inhibitors, VIP 0.38 (95% CI 0.33-0.54) nmol/kg animal, resulted in a 50% decrease in PaO and 33% of a 1 nmol/kg VIP dose was recovered as intact VIP. In the presence of two combinations of enzyme inhibitors, SCH 32615 (S, 10 microM) and aprotinin (A, 500 tyrpsin inhibitor units [TIU]/kg) or S and soybean trypsin inhibitor (T, 500 TIU/kg), VIP caused a significantly greater decrease in PaO and greater quantities of VIP were recovered from lung effluent (both P < 0.001). The addition of captopril, (3 microM), leupeptin (4 microM), or bestatin (1 microM) failed to further increase pulmonary relaxation or recovery of VIP-LI. When given singly, A, T, and S did not augment the effects or recovery of VIP. The efficacy of S (a specific inhibitor of neutral endopeptidase [NEP]) and A and T (serine protease inhibitors) thus implicated NEP and at least one serine protease as primary modulators of VIP activity in the guinea pig lung. We sought to corroborate this finding by characterizing the predominant amino acid sites at which VIP is hydrolized in the lung. When [mono(125I)iodo-Tyr10]VIP was offered to the lung, in the presence and absence of the active inhibitors, cleavage products consistent with activity by NEP and a tryptic enzyme were recovered. These data demonstrate that NEP and a peptidase with an inhibitor profile and cleavage pattern compatible with a tryptic enzyme inactivate VIP in a physiologically competitive manner.
在离体灌注的豚鼠肺中,研究了酶抑制剂对血管活性肠肽(VIP)诱导的气道开放压(PaO)降低和VIP样免疫反应性(VIP-LI)恢复的影响。在无抑制剂时,0.38(95%可信区间0.33 - 0.54)nmol/kg动物的VIP可使PaO降低50%,且1 nmol/kg VIP剂量的33%以完整VIP形式恢复。在存在两种酶抑制剂组合,即SCH 32615(S,10 μM)和抑肽酶(A,500胰蛋白酶抑制剂单位[TIU]/kg)或S和大豆胰蛋白酶抑制剂(T,500 TIU/kg)的情况下,VIP导致PaO显著更大程度降低,且从肺流出液中回收的VIP量更多(两者P < 0.001)。添加卡托普利(3 μM)、亮抑肽酶(4 μM)或贝司他汀(1 μM)未能进一步增加肺舒张或VIP-LI的恢复。单独给予时,A、T和S并未增强VIP的作用或恢复。S(中性内肽酶[NEP]的特异性抑制剂)以及A和T(丝氨酸蛋白酶抑制剂)的作用表明,NEP和至少一种丝氨酸蛋白酶是豚鼠肺中VIP活性的主要调节因子。我们试图通过确定肺中VIP水解的主要氨基酸位点来证实这一发现。当向肺中加入[单(125I)碘酪氨酸10]VIP时,无论有无活性抑制剂,均回收了与NEP和一种胰蛋白酶活性一致的裂解产物。这些数据表明,NEP和一种具有与胰蛋白酶抑制剂谱及裂解模式相符的肽酶以生理竞争方式使VIP失活。